concordance with the known effects of conventional ECT in PD, 5 we hypothesized that patients would significantly improve in both mood and motor function with RUL UBP ECT. We also hypothesized that acute and subacute adverse cognitive effects of RUL UBP ECT would be substantially reduced in severity compared to published side effects in patients receiving conventional bilateral ECT.
| MATERIALS AND METHODS

| Participants
Participants (N=6) were recruited from either the psychiatry clinic or the movement disorders clinic during routine appointments at the Medical University of South Carolina (MUSC). We informed participants about the risks and benefits of all treatment options, including ECT, and described the purpose and design of the study to each patient in detail; patients provided signed informed consent to participate. The institutional review board at MUSC approved this study before any study procedures began, and the study was performed in accordance with the declaration of Helsinki.
| Inclusion criteria
We screened participants for major inclusion criteria in person in the clinic during their regularly scheduled appointments.
Participants must have had a diagnosis of PD made by a neurologist specializing in the treatment of movement disorders and meeting UK Brain Bank Criteria. 9 Participants must have had documented motor fluctuations and/or ≥4 years of diagnosed PD. Participants also were required to have either significant comorbid depression as measured by the Geriatric Depression Scale (GDS-30) or psychosis as measured by Clinical Global Impression Scale. Finally, patients had to meet clinical criteria for ECT, which included either medically refractory major depression or psychosis or both.
| ECT parameters and protocol
We used glycopyrrolate (0.1 mg), methohexital (1.0 mg/kg), and 
| Study design and assessment scales
The raters were independent from the ECT treating physicians.
Participants received a global assessment for severity of PD, psychiatric comorbidities, and cognitive dysfunction at baseline, which included the following scales: the Unified Parkinson's Disease Rating Scale (UPDRS), GDS-30, 12 Hamilton Depression Rating Scale (HAM-D-17) for depression, 12 Scale for the Assessment of Positive Symptoms (SAPS), 13 Questionnaire for Impulsive-Compulsive Disorders in PD, 14 Scale for Suicidal Ideation (SSI), 15 Apathy Scale score compared to baseline, and remission was defined as a total score of ≤7. Response as per the GDS-30 was defined as a total score of ≤4.
| Data analysis
The primary goal of this study was to conduct a within-subjects analysis of scores before and after ECT treatment. Timepoints of interest included: (1) baseline, (2) after final treatment, and (3) 1 month after final treatment. For each measure of interest, the change in score from baseline to each follow-up timepoint was calculated. A last-value-carried-forward approach was used to handle missing data. Due to the small sample size, nonparametric Wilcoxon signed-rank tests were used to determine if median changes in scores were significant, and an α value of .10 was used to determine statistical significance.
| RESULTS
Six patients completed the study with measures taken at baseline, immediately after ECT, and 1 month after ECT. One participant was excluded from analysis because on review the subject did not meet UK brain bank criteria. Patient demographics are presented in Table 1 . Patient demographics are presented in Table 1 .
Mean age was 69.8 years, with 7.6 mean years of PD and 23.7
mean years of depression. Baseline mean scores, scores following ECT, and scores at 1-month follow-up are shown in Table 2 
| DISCUSSION
This open-label pilot study demonstrates that RUL UBP ECT is safe, feasible, and potentially efficacious in treating multiple domains of PD, including motor and mood, without clear cognitive side effects. Specifically, we found that patients improved significantly in their mood as measured by the HRSD and GDS. The mean HRSD score of this cohort was well within the range of severe depression at baseline (>24); however, this score fell to the lowest level of mild depression (~8) immediately following ECT and then fell further into the non-depressed range (<7) at 1-month followup. 18 Similarly, patients no longer met criteria for depression under the GDS immediately after and 1 month following ECT. 19 In line with these improvements in mood, we found that levels of apathy on the AS significantly improved to low, clinically insignificant levels. 16 SSI levels also decreased, although not significantly in this small cohort. It is important to note that three of the 6 patients in this cohort had deep brain stimulation electrodes implanted, which did not have any bearing of safety or tolerability.
The mechanism of ECT-induced mood improvements may be unique in PD-related depression, as the natural history of PD-related depression differs from other etiologies. 20, 21 Depression in PD may be responsive to dopamine agonism, 22 a unique effect that could be due to a relative hypodopaminergic state within not only the motor but also the mood neurocircuitry. 23 Thus, the mechanism of ECT in treating PD-related depression may be a result of increased dopamine receptor binding caused by electroconvulsive stimulation in brain regions implicated in depression such as the nucleus accumbens. 24, 25 It is likely that the antidepressant mechanism of ECT is not completely unique in patients with PD.
26
We observed significant improvements in psychosis following ECT.
Psychosis is particularly common in patients with advanced PD who have been treated with dopaminergic agonists for long durations. 27 Similarly to typical antipsychotics, ECT likely exerts its antipsychotic effect through attenuated D2 signaling, 28 as ECT has been shown to reduce D2 receptor binding in the anterior cingulate. 29 Furthermore, ECT may produce an antipsychotic effect through reduced 5HT2A receptor density. in PD through the facilitation of D1 and D3 binding in the striatum. 32 Additionally, ECT has been shown to increase cortical GABA concentrations.
33
We observed no deficits in cognitive functioning with RUL UBP ECT. Indeed, MOCA scores transiently increased after the ECT course was concluded and returned to baseline 1 month following ECT. We 
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